Inogen (INGN) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | Inogen | 165.85 Mn | 71.44 Mn | 37.86 Mn | -2.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.70% |
| Dec 31, 2025 | 59.85% |
| Sep 30, 2025 | 33.80% |
| Jun 30, 2025 | 2.68% |
| Mar 31, 2025 | 2.07% |
| Dec 31, 2024 | -45.57% |
| Sep 30, 2024 | 54.53% |
| Jun 30, 2024 | -17.16% |
| Mar 31, 2024 | -61.05% |
| Dec 31, 2023 | -68.54% |
| Sep 30, 2023 | -34.45% |
| Jun 30, 2023 | -35.54% |
| Mar 31, 2023 | -89.26% |
| Dec 31, 2022 | -70.47% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -42.04% |
| Mar 31, 2022 | -87.55% |
| Dec 31, 2021 | 9.34% |
| Sep 30, 2021 | -30.54% |
| Jun 30, 2021 | -9.51% |
| Mar 31, 2021 | -35.07% |
| Dec 31, 2020 | 0.32% |
| Sep 30, 2020 | -38.81% |
| Jun 30, 2020 | -5.01% |
| Mar 31, 2020 | -27.54% |
| Dec 31, 2019 | 8.19% |
| Sep 30, 2019 | 23.46% |
| Jun 30, 2019 | 14.75% |
| Mar 31, 2019 | -38.88% |
| Dec 31, 2018 | -39.51% |
| Sep 30, 2018 | 24.02% |
| Jun 30, 2018 | 237.67% |
| Mar 31, 2018 | 22.65% |
| Dec 31, 2017 | 57.59% |
| Sep 30, 2017 | 77.73% |
| Jun 30, 2017 | 24.17% |
| Mar 31, 2017 | 118.41% |
| Dec 31, 2016 | 47.84% |
| Sep 30, 2016 | -3.45% |
| Jun 30, 2016 | 213.36% |
| Mar 31, 2016 | 120.10% |